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Abstract
Fabry Disease, an X-linked inborn error of metabolism, is characterized by progressive renal insufficiency, with
cardio and cerebrovascular involvement. Homocysteine (Hcy) is considered a risk factor for vascular diseases, but
the mechanisms by which it produces cardiovascular damage are still poorly understood. Regarding the vascular in-
volvement in FD patients, the analysis of factors related to thromboembolic events could be useful to improving our
understanding of the disease. The aim of this study was to evaluate plasma Hcy and other parameters involved in the
methionine cycle, as well as oxidative stress markers. The sample consisted of a group of 10 male FD patients and a
control group of 8 healthy individuals, paired by age. Venous blood was collected for Hcy determination, molecular
analysis, identification of thiobarbituric acid reactive substances, total glutathione and antioxidant enzymes activity,
as well as vitamins quantification. Comparative analysis of FD patients versus the control group indicated
hyperhomocysteinemia in 8 of the 10 FD patients, as well as a significant increase in overall glutathione levels and
catalase activity. It is inferred that FD patients, apart from activation of the antioxidant system, present increased lev-
els of plasma Hcy, although this is probably unrelated to common alterations in the methionine cycle.
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Introduction
Fabry Disease (FD) is an X-linked inborn error of
glycosphingolipid metabolism caused by deficient lyso-
somal enzyme -galactosidase A activity. As a result, neu-
tral glycosphingolipid globotriaosylceramide (Gb3) accu-
mulates in the liver, heart, spleen and kidneys, especially in
lysosomes of vascular endothelium and plasma (Desnick et
al., 2001; Desnick et al., 2003).
The disease is pan-ethnic, with the incidence of clas-
sical phenotypes estimated to be around 1:40,000, although
a study with a newborn screening sample has found an inci-
dence of 1:3,100 (Spada et al., 2006). FD predominantly af-
fects males (hemizygous), although carrier (heterozygous)
females can also be affected to a mild or even severe extent
(Whybra et al., 2001; Desnick et al., 2003). FD is character-
ized by progressive renal insufficiency, leading to morbid-
ity through cardio- and cerebrovascular involvement.
Major manifestations include paresthesia in the extremi-
ties, corneal dystrophy, angiokeratoma and occlusive vas-
cular disease of the heart, kidney and brain, leading to
premature death.
Apart from thrombogenic factors, which can also
play a significant role in FD vascular pathology (Demuth
and Germain, 2002), FD patients present an increased inci-
dence of arterial thrombosis, mainly due to the progressive
deposition of Gb3 in vascular endothelium and smooth
muscle cells (Hughes and Mehta, 2005).
Whereas homocysteine (Hcy), a sulfur containing
amino acid formed during methionine metabolism, is con-
sidered by some authors as a risk factor in vascular diseases
(Refsum et al., 1998; Homocysteine Studies Collaboration,
2002; Lentz and Haynes, 2004), hyperhomocysteinemia
(HHcy), at a plasmatic concentration higher than
15 mol/L has also been associated with disorders, such as
venous thrombosis, ischemic heart disease, atherothrom-
bosis and strokes (Morelli et al., 2002; Lentz and Haynes,
2004; Eldibany and Caprini, 2007).
Although the mechanisms by which Hcy induces car-
diovascular damage are still poorly understood, those
known include endothelial dysfunction, and the oxidative
stress process (Welch and Loscalzo, 1998; Voutilainen et
al., 1999; Sharma et al., 2006). Cysteine (Cys) (Homo-
cysteine Studies Collaboration, 2002), another sulfur con-
taining amino acid involved in methionine metabolism, has
also been associated with oxidative stress conditions (Jo-
nes, 2006).
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These oxidative stress conditions, defined by disrup-
tion of the physiological balance between oxidants and an-
tioxidants, potentially lead to cellular damage. Some
authors propose that Hcy induced oxidative stress is pri-
marily caused by detoxification and intracellular antioxi-
dant enzyme deficiency (Sharma et al., 2006).
Oxidative stress seems to play a role in the patho-
physiology of several inborn errors of metabolism, such as
phenylketonuria, maple syrup disease and homocystinuria
(Ristoff and Larsson, 2002; Sirtori et al., 2005; Barschak et
al., 2006). An increase in the antioxidant enzyme activity
catalase (CAT) has been observed in two other lysosomal
storage disorders, Gaucher Disease and Mucopolysaccha-
ridosis type I (Roversi et al.,2006; Pereira et al., 2008).
Considering that vascular involvement is an impor-
tant characteristic in FD patients, the aim here was to evalu-
ate total plasma concentrations of Hcy and Cys, other fac-
tors involved in the methionine cycle (vitamin B12, folic
acid and the C677T polymorphism of methylenetetrahy-
drofolate reductase - MTHFR), and oxidative stress mark-
ers, i.e., total glutathione, lipid peroxidation and antioxi-
dant enzymes (CAT, superoxide dismutase - SOD and
glutathione peroxidase - GPx), to so be able to evaluate the
role of these parameters in FD patients.
Material and Methods
Subjects
The sample consisted of two groups: 10 male FD pa-
tients, from 16 to 70 years old (termed FD group), and eight
healthy male volunteers, from 18 to 60 years old (termed
control group – CG). Patients were selected from the 1°
Encontro Brasileiro de Familiares e Portadores da Doen-
ça de Fabry (1st Brazilian meeting of Fabry disease pa-
tients and relatives), bringing together patients and
relatives countrywide, and which took place at the Univer-
sidade Federal de São Paulo (UNIFESP). Healthy
volunteers were selected from among the UNIFESP staff.
All the FD patients participated voluntarily, after hav-
ing given written informed consent. Diagnosis was con-
firmed by enzymatic activity assay and/or molecular
analysis. Besides kinship (three pairs of siblings), six indi-
viduals were undergoing enzyme replacement therapy at
the time of the study (Table 1).
The study took place at the Centro de Referência em
Erros Inatos do Metabolismo (CREIM). The research pro-
tocols and consent forms, as well as the overall investiga-
tion, were ethically and scientifically approved by the
Medical Research and Ethical Committee of UNIFESP.
Venous blood from each patient was collected in
three different tubes, one containing EDTA, another hepa-
rin and the third without anticoagulant. Leukocytes and
plasma from the EDTA tubes were separated by centri-
fugation at 1000xg for 10 min. Plasma was used for Hcy
and Cys quantification, and leukocytes for DNA extraction
prior to polymorphism analysis. Red blood cells (RBC) and
plasma from tubes containing heparin were separated by
centrifugation at 1000xg for 6 min at 4 °C. The plasma was
immediately used for lipid peroxidation analysis, whereas
the RBCs were stored at -80 °C for posterior total gluta-
thione and antioxidant enzymes assay. A hemolysate of
RBC for each sample was prepared by washing and lysing
these cells.
An aliquot of these hemolysates was used for antioxi-
dant enzymes assay, and another mixed with HClO4 2 M
EDTA 4 mM for the analysis of total glutathione (tGSH).
Serum separated from tubes without anticoagulant was
used for vitamin B12 and folic acid quantification. Urine
samples were collected from eight patients and stored at
-80 °C prior to analysis of Hcy and Cys excretion (Cya-
nide-Nitroprusside test).
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Table 1 - Characteristics of the Fabry Disease patients.
FD patients Age ERT# Relationship Angiokeratoma Cornea
verticilata
Acroparestesia Hypohidrosis Proteinuria Vascular
events†
1 26 NO 2; 5 + x + + + YES
2 31 5 1; 5 + x + + + NO
3 33 10 + x + + + NO
4 47 2 12 + + + + + NO
6 73 NO + + + + + NO
10 20 NO 7 NO
11 46 NO + + + + + NO
12 46 2 4 + - + + + NO
14 36 2 9; 13; 15; 16 + + + + + NO
16 49 5 9; 13; 14; 15 x + + + + NO
All the symptoms were obtained from the Fabry Registry (patient 10 not included in Fabry Registry); +: manifestation present; -: manifestation not oc-
curs; x: data not accessed. Age (years) at the time of sample collection. ERT: enzyme replacement therapy; #: time in months until the collection. †: data
until 2007 (from the Fabry Registry).
Biochemical analysis
Thiobarbituric acid reactive substances (TBARS)
were quantified in plasma for lipid peroxidation analysis
(Ohkawa et al., 1979). Results were expressed as nmol of
malondialdehyde/mL. The tGSH assay was carried out ac-
cording to the method described by Tietze (1969). Samples
were analyzed spectrophotometrically and results ex-
pressed as mol/g hemoglobin (Hb). CAT activity assay
was according to the method described by Adamo et al.
(1989). Activity values were expressed as units per milli-
gram of hemoglobin (U/mg Hb). GPx activity levels were
measured using the method described by Sies et al. (1979),
and the results expressed as U/g Hb. SOD activity was as-
sayed using the method described by McCord and
Fridovich (1969), and the result calculated as U/mg Hb.
Evaluation of Hcy and Cys concentrations in plasma,
according to the method described by Guerra-Shinohara et
al. (2002), was performed with high performance liquid
chromatography. Concentrations were given as M. Quan-
tification of vitamin B12 was performed by immunoassay
with the Roche Diagnostics kit (Elecsys® 2010 – Vitamin
B12). Folic acid was quantified by HPLC(Kelly and Davis,
1964). Concentrations of both vitamins were given as
pg/mL and ng/mL, respectively.
Cyanide-Nitroprusside testing was performed ac-
cording to the method described by Shih et al. (1991).
Molecular analysis
Genomic DNA was obtained from peripheral blood
samples, according to the method described by Miller et al.
(1988). Analysis of MTHFR gene C677T polymorphism
was by polymerase chain reaction (PCR) and restriction
fragment length polymorphism analysis. Primers were de-
scribed by Goyette et al. (1995). The final PCR product was
digested with the restriction enzyme Hinf I.
Statistical analysis
Data were expressed as means  standard deviation
(SD). The Student t test for two independent samples was
applied for analyzing the means of FD patients versus CG.
The significance level was set at five percent. All the analy-
ses were with STATISTICA 6.0 for Windows software.
Results
The Fabry patients clinical and demographic data
(Table 1) were obtained from questionnaires applied during
the day of sample collection, and supplemented by infor-
mation from the Fabry Registry sponsored by the Genzyme
Corporation.
All the biochemical parameters in the 10 male FD pa-
tients were analyzed, and the results subsequently com-
pared to data obtained from CG (n = 8 male volunteers).
Regarding Hcy levels, the average result observed in the
FD group was significantly higher than that observed in CG
(p = 0.0093; FD group: 22.20  8.40 – without outlier; CG:
11.35  2.82). Worthy of note, one of the patients presented
a much higher Hcy value than the average (252.64), thereby
justifying exclusion from analysis. On applying the defini-
tion of HHcy, a significant increase could be observed in
eight of the 10 FD patients (Figure 1). Cys quantification,
applied to FD patients and CG alike, indicated no apparent
difference between the two groups (p = 0.6494; FD group:
508.60  92.46; CG: 485.41  110.54).
With the exception of three patients with B12 levels
below the normal range (Vitamin B12: 228.60  89.77
pg/mL – reference: 180-950 pg/mL; Folic acid:
6.37  0.89 ng/mL – reference: 1.8-9.0 ng/mL), vitamin
B12 and folic acid quantification with FD group samples
presented averages for both parameters, which could be
considered as in accordance with reference values ob-
tained from the laboratory responsible for determination
(VITAE Cromatografia Líquida em Análises Clínicas
LTDA, São Paulo, Brazil).
MTHFR C677T polymorphism was observed in five
of the FD patients. Concerning oxidative stress parameters,
a significant increase in tGSH levels and CAT activity was
observed, when compared to CG (Table 2).
Discussion
Plasma Hcy levels higher than15 mol/L were ob-
served in 80% of the FD samples. According to the litera-
ture, in the population as a whole, there are many reasons
for this increase, such as vitamin deficiency and mutation in
those genes that encode enzymes from the methionine cy-
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Figure 1 - Homocysteine concentration values in FD and CG. Data are
from FD patients, but excluding the outlier value (252.64 M). An asterisk
indicates statistically significant differences between FD patients and CG
(p = 0.0093). The shaded area represents the normal Hcy concentration.
cle, being among the most frequent (Lentz and Haynes,
2004; Eldibany and Caprini, 2007).
Quantification of vitamin B12 and folic acid, as well
as analysis of MTHFR C677T polymorphism, were used to
assess any relationship between alterations in these param-
eters and HHcy. Although the average levels of both vita-
mins in FD patients were in accordance with the reference
value range, three patients presented low vitamin B12 lev-
els. Considering that these three patients presented HHcy,
vitamin alteration could probably be responsible for this.
Since vitamin B12 deficiency has not been observed previ-
ously among FD patients (Sheth et al., 1981; Fedi et al.,
2005), our findings deserves consideration. As to MTHFR
polymorphisms, it was impossible to establish a direct rela-
tionship between the presence of the T allele and HHcy. Of
the five unrelated patients found to be heterozygous for this
allele, only three presented HHcy.
Since an increase in plasma Hcy levels was noted, it
was decided to check for any parallel increase in Hcy excre-
tion, a characteristic of patients with homocystinuria. As
the Cyanide-Nitroprusside test shows the presence of sul-
fur-containing amino acids in urine, this was applied to ana-
lyze both Hcy and Cys excretion. No alteration was found
in the urine from the six FD patients presenting HHcy. As
the kidney is essential for Hcy clearance and metabolism, it
is possible that the renal damage observed in FD patients
contributes to the imbalance of Hcy levels (Friedman et al.,
2001).
It is important to describe one particular case ob-
served during the study. One subject presented a very high
Hcy level (252.64 M), but with no increase in Hcy and/or
Cys excretion detectable by the Cyanide-Nitroprusside test.
Although the patient presented vitamin B12 levels below
the normal range and was heterozygous for MTHFR gene
C677T polymorphism, these factors could not account for
such a high Hcy level. Hence, there is the possibility of this
alteration arising from renal damage, since the individual
presented no symptoms of homocystinuria. Nevertheless,
Hcy levels >200 M are compatible with this inborn error
of metabolism (Refsum et al., 1998).
The relationship between HHcy and increased cardio-
vascular risk is widely known (Refsum et al., 1998; Welch
and Loscalzo, 1998; Homocysteine Studies Collaboration,
2002). In a study published in 2002, an increase in Hcy lev-
els was observed in FD patients (Demuth and Germain,
2002), yet the authors did not include subjects with kidney
insufficiency, and failed to supply pertinent information re-
garding more premature stages of renal damage. HHcy was
also observed when comparing FD patients versus CG, al-
though in this case the decrease in vitamin B6 and folic acid
levels was considered to account for the alteration (Fedi et
al., 2005). One limitation in our study was the lack of infor-
mation regarding renal function in the patients, thus limit-
ing any assessment of the possible relationship between
HHcy and renal failure.
There was no significant difference in TBARS plas-
ma levels, a marker of lipid peroxidation, and thus indica-
tive of oxidative stress. However, an increase in tGSH
levels and CAT activity was observed among FD patients,
thereby implying activation of the antioxidant system.
A similar activation of antioxidant defense in Gau-
cher disease and Mucopolysaccharidosis type l (MPS l) pa-
tients, had already been demonstrated by our group (Ro-
versi et al., 2006; Pereira et al., 2008). Furthermore, an
increase in CAT activity and a decrease in SOD activity had
been observed in Gaucher Disease patients undergoing en-
zyme replacement therapy (ERT) (Roversi et al., 2006).
Upon evaluating MPS I patients before starting ERT and up
to 24 weeks of infusion, the increase in CAT activity was
seen to occur after the beginning of the treatment, thereby
indicating that activation of the antioxidant system may be
a direct consequence of ERT (Pereira et al., 2008).
Hence, as 60% of the FD group was composed of pa-
tients undergoing ERT, activation of antioxidant defense
observed among these may also be associated to the treat-
ment. Corroborating this hypothesis, a recent study (Shen
et al., 2008) demonstrated that incubation of cells with re-
combinant -galactosidase A led to an increase in the pro-
duction of reactive oxygen species (ROS), thus in accor-
dance with the previous results from our group (Roversi et
al., 2006; Pereira et al., 2008). Furthermore, it was demon-
strated that Gb3 also induces the increased production of
ROSs, when added to the cell culture medium. This exces-
sive ROS generation apparently being linked with the in-
volvement of vascular endothelial cells, resulting in the de-
velopment of atherosclerosis and other cardiovascular
disorders frequently encountered in FD patients.
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Table 2 - Oxidative stress data obtained from FD patients and CG.
Fabry Disease patients Control group
Total Glutathione (mmol/g Hb) 6.37  0.89* 4.77  0.94
Lipid peroxidation (nmol MDA/mL) 1.13  0.46 1.41  0.39
Catalase (U/mg Hb) 97.02  17.47* 73.04  22.66
Superoxide Dismutase (U/mg Hb) 15.79  3.35 15.74  3.23
Glutathione Peroxidase (mU/mg Hb) 11.08  0.90 10.60  5.16
Data are expressed in mean +/- SD. Statistical p values were obtained with the Student t test. *p value < 0.05.
In conclusion, our results suggest that FD patients
present increased levels of plasma Hcy, probably unrelated
to common alterations in the methionine cycle, as well as
activation of the antioxidant system.
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